Ulixertinib hydrochloride is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a potent and selective inhibitor of the ERK (extracellular signal-regulated kinase) pathway, which is often dysregulated in various cancers. By blocking ERK signaling, it helps to inhibit tumor growth and proliferation, particularly in cancers driven by mutations in the MAPK pathway, such as melanoma, colorectal cancer, and pancreatic cancer. It is being investigated in clinical trials for its efficacy in treating solid tumors, especially those resistant to other therapies. Additionally, it shows potential in combination therapies, enhancing the effects of other anticancer drugs and overcoming drug resistance mechanisms.